From the horse's mouth ( and not an email to friends) announced to the market less than a month ago in their April Investor Presentation..........
""Phase IIb trial (63 patients) for ovarian cancer patients after successful 1st or 2nd line therapy has completed recruiting patients in U.S. & Australia to:
–Assure comparability of multiple manufacturing centers
–Confirm safety & tolerability established in earlier trials
–Compare CVac to standard of care (progression-free survival)
–Confirm host immunologic response to CVac therapy
–Recruitment completed in September 2011
–Interim PFS Data in 2012
–Final PFS Data anticipated in 2013""
- Forums
- ASX - By Stock
- IMM
- wednesday 9 may
wednesday 9 may, page-7
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
RCE
Phase II clinical trial recruitment for R327G topical gel passes halfway, showing promising results against bacterial skin infections
LU7
The Breakdown: Lithium Universe talks refinery design and lithium processing in strong preliminary feasibility study for Bécancour
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
31.5¢ |
Change
0.005(1.61%) |
Mkt cap ! $458.1M |
Open | High | Low | Value | Volume |
31.0¢ | 32.0¢ | 30.5¢ | $694.0K | 2.223M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 22530 | 31.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
31.5¢ | 176372 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 22530 | 0.310 |
21 | 379601 | 0.305 |
32 | 821817 | 0.300 |
9 | 158083 | 0.295 |
10 | 237886 | 0.290 |
Price($) | Vol. | No. |
---|---|---|
0.315 | 176372 | 4 |
0.320 | 104699 | 4 |
0.325 | 108599 | 5 |
0.330 | 199775 | 4 |
0.335 | 196676 | 5 |
Last trade - 16.10pm 09/10/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |
The Watchlist
AHK
ARK MINES LIMITED
Ben Emery, Executive Director
Ben Emery
Executive Director
SPONSORED BY The Market Online